Sign in
CompletedPhase 2

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

Key facts

Who runs it
VivaVision Biotech, Inc
Where
Austin, Cincinnati, Grand Junction, Houston, Inglewood, Jacksonville, Las Vegas, Petaluma, Rancho Cordova, and Washington, United StatesSee the 10 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
91 people enrolled
Started
11 Jan 2024
Ended
15 May 2024
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • VVN461 Ophthalmic Solution 1.0%
  • VVN461 Ophthalmic Solution 0.5%
  • Vehicle
Record updated
11 September 2026

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • ≥21 years of age and in good general health at Visit 1 (Screening)
  • Willing and able to provide informed consent and provide relevant privacy authorization(s)
  • Willing and able to comply with study requirements and visit schedule
  • Clear ocular media (other than cataract) in the study eye
  • Planning to undergo routine unilateral cataract surgery via phacoemulsification extraction and implantation of an intraocular lens

Who cannot take part

  • Recent use of corticosteroids or oral non-steroidal anti-inflammatory drugs
  • Any ocular pain at Visit 1 (Screening)

Where in United States

  • Keystone ResearchAustin, United States
  • Cincinnati Eye InstituteCincinnati, United States
  • ICON Eye CareGrand Junction, United States
  • Houston Eye AssociatesHouston, United States
  • United medical research instituteInglewood, United States
  • Levenson Eye AssociatesJacksonville, United States
  • Center for Sight Las VegasLas Vegas, United States
  • North Bay Eye AssociatesPetaluma, United States
  • Martel Eye AssociatesRancho Cordova, United States
  • Comprehensive Eye Care, Ltd.Washington, United States

About the trial

What the trial wants to find out

This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement (CELR) surgery via phacoemulsification

The 3 groups in the trial

  • VVN461 1.0%Treatment being tested

    VVN461 Ophthalmic Solution, 1.0%

    Treatment: VVN461 Ophthalmic Solution 1.0%

  • VVN461 0.5%Treatment being tested

    VVN461 Ophthalmic Solution, 0.5%

    Treatment: VVN461 Ophthalmic Solution 0.5%

  • VehiclePlacebo, for comparison

    VVN461 Vehicle

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Double-masked, Randomized, Vehicle-controlled Study of VVN461 Ophthalmic Solution in Treating Post -Operative Ocular Inflammation in Subjects Undergoing Routine Unilateral Cataract Surgery
Record updated
11 September 2026